Win-Win Fine Chemical Expert

A Tirezepatide Equivalent! Major Domestic Weight-Loss Drug Achieves Topline Results

On May 5, 2026, Borui Pharmaceutical, an innovative drug company listed on the STAR Market, announced that its independently developed GLP-1/GIP dual receptor agonist—BGM0504 Injection—achieved positive topline results in a Phase III clinical study (Project No.: BGM0504-III-WL) designed to evaluate its efficacy and safety in overweight or obese subjects. BGM0504 is a GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) dual receptor agonist independently developed by the company; it activates downstream pathways to elicit biological effects such as blood glucose control, weight loss, and the treatment of metabolic dysfunction-associated steatohepatitis (MASH).

Read More...

The Domestic GLP-1 Arena: Has a "Trump Card" Just Emerged?

As global competition within the GLP-1 landscape reaches a fever pitch, weight loss is no longer the sole objective; rather, cardiovascular-metabolic benefits and tolerability have emerged as key differentiators. Recently, Borui Pharmaceutical announced positive top-line results from BGM0504-III-WL—a Phase III clinical trial evaluating BGM0504 Injection, its independently developed dual GLP-1/GIP receptor agonist. The data reveals that the drug not only demonstrated exceptional efficacy in terms of weight loss and waist circumference reduction but also exhibited superior comprehensive capabilities in cardiovascular-metabolic regulation. Furthermore, it boasted an extremely low discontinuation rate, and—remarkably—led to an increase rather than a decrease in bone mineral density. These results position BGM0504 as a strong contender to become the next "trump card" product in the GLP-1 market.

Read More...

Global’s First Biased GLP-1 Weight-Loss Drug, Xianweiying, Approved for Launch!

On March 6, 2026, a biopharmaceutical company dedicated to the discovery and development of innovative therapies for metabolic diseases announced that Enoglutide Injection (Xianweiying)—the world’s first cAMP-biased GLP-1 receptor agonist—has received market approval from the National Medical Products Administration (NMPA). It is indicated for the long-term weight management of overweight or obese adults, to be used in conjunction with a reduced-calorie diet and increased physical activity.

Read More...

Hehuang Pharmaceuticals' Furoquitinib 'Approved for Market by FDA

On November 9th, Hehuang Pharmaceutical announced FRUZAQLA ? Furuintinib has been approved by the FDA for marketing, becoming the first and only highly selective inhibitor for all three types of VEGF receptor kinases approved for the treatment of metastatic colorectal cancer in the United States, regardless of the patient's biomarker status.

Read More...

CPHI World Wide2023

October 24-26, 2023, the world's largest pharmaceutical industry professional exhibition CPhI Worldwide will be held in Barcelona, Spain, the exhibition has been the world's pharmaceutical raw material industry practitioners active participation and widely recognized, become the world's pharmaceutical raw material industry practitioners annual gathering.

Read More...

Dazhe Pharmaceutical JAK1 inhibitor "Gulisidinib" domestic newspaper listing

On September 14, CDE's official website showed that Dazhe Pharmaceutical's high -selective JAK1 inhibitor Goriqitini new drug listing application has been accepted for the treatment of recurrence and refractory perimeter T cell lymphoma (R/R PTCL) Essence According to Dazhe's press release, this is the source innovative drug reported by the company's 2nd. Gulifitinib is the world's first high -selective JAK1 inhibitor in the world of T -cell lymphoma and so far in the NDA declaration stage. It has conducted key clinical trials in China, the United States, South Korea, and Australia.

Read More...